Posted by Michael Wonder on 18 Sep 2024
Biogen's new drug submission for omaveloxolone accepted for priority review by Health Canada for the treatment of Friedreich's ataxia
17 September 2024 - If approved, omaveloxolone would be the only disease specific treatment option for patients living with this progressive and challenging disease.
Biogen Canada is pleased to announce today that Health Canada has accepted for priority review its new drug submission for omaveloxolone, an innovative therapy for Friedreich's ataxia for the treatment of adults and adolescents aged 16 years and older.
